Skip to main content
. 2017 Aug 5;1(2):202–215. doi: 10.1002/rth2.12029

Figure 4.

Figure 4

Arithmetic mean plasma concentration–time profiles. (A) Total dabigatran, unbound dabigatran, and active dabigatran in the absence (day 4) or presence (day 11) of idarucizumab 2.5+2.5 g. (B) Unbound dabigatran in the absence (day 4) or presence (day 11) of idarucizumab 1, 2, 4, and 5 g at dabigatran steady state (semi‐log‐scale). DE, dabigatran etexilate